Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis
Joseph A. Pidala(Moffitt Cancer Center), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jongphil Kim(Moffitt Cancer Center), Mehdi Hamadani(Medical College of Wisconsin), Kuo‐Kai Chin(Memorial Sloan Kettering Cancer Center), Nosha Farhadfar(University of Florida Health), Corey Cutler(Harvard University), Gulrayz Ahmed(Medical College of Wisconsin), Eneida R. Nemecek(Oregon Health & Science University), Muna Qayed(Emory University), Zachariah DeFilipp(Harvard University), Iskra Pusic(Washington University in St. Louis), Aaron Etra(Icahn School of Medicine at Mount Sinai), Betty K. Hamilton(Cleveland Clinic), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Anthony D. Sung(Duke University), Doris M. Ponce(Memorial Sloan Kettering Cancer Center), Denise Kalos(Moffitt Cancer Center), Carrie L. Kitko(Vanderbilt University Medical Center), William J. Hogan(Mayo Clinic), Mary ED Flowers(Fred Hutch Cancer Center), Najla El Jurdi(University of Minnesota), Marcello Rotta(Colorado Blood Cancer Institute), Helen Tang(University of Pennsylvania)
Cited by 16
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k